American Journal of Cardiology
Volume 103, Issue 3 , Pages 307-311, 1 February 2009

Relation of Death Within 90 Days of Non-ST-Elevation Acute Coronary Syndromes to Variability in Electrocardiographic Morphology

  • Zeeshan Syed, MEng

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts
    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
  • ,
  • Benjamin M. Scirica, MD, MPH

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Satishkumar Mohanavelu, MS

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Phil Sung, SB

      Affiliations

    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
  • ,
  • Eric L. Michelson, MD

      Affiliations

    • AstraZeneca LP, Wilmington, Delaware
  • ,
  • Christopher P. Cannon, MD

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Peter H. Stone, MD

      Affiliations

    • TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
  • ,
  • Collin M. Stultz, MD, PhD

      Affiliations

    • Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts
    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
  • ,
  • John V. Guttag, PhD

      Affiliations

    • MIT Department of Electrical Engineering and Computer Science, Cambridge, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-253-6022; fax: 617-253-8460

Received 28 July 2008; received in revised form 12 September 2008; accepted 12 September 2008. published online 21 November 2008.

Electrocardiographic measures can facilitate the identification of patients at risk of death after acute coronary syndromes. This study evaluates a new risk metric, morphologic variability (MV), which measures beat-to-beat variability in the shape of the entire heart beat signal. This metric is analogous to heart rate variability (HRV) approaches, which focus on beat-to-beat changes in the heart rate. MV was calculated using a dynamic time-warping technique in 764 patients from the DISPERSE2 (TIMI 33) trial for whom 24-hour continuous electrocardiograph was recorded within 48 hours of non-ST-elevation acute coronary syndrome. The patients were evaluated during a 90-day follow-up for the end point of death. Patients with high MV showed an increased risk of death during follow-up (hazard ratio 8.46; p <0.001). The relationship between high MV and death could be observed even after adjusting for baseline clinical characteristics and HRV measures (adjusted hazard ratio 6.91; p = 0.001). Moreover, the correlation between MV and HRV was low (R ≤0.25). These findings were consistent among several subgroups, including patients under the age of 65 and those with no history of diabetes or hyperlipidemia. In conclusion, our results suggest that increased variation in the entire heart beat morphology is associated with a considerably elevated risk of death and may provide information complementary to the analysis of heart rate.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported, in part, by Center for Integration of Medicine and Innovative Technology, Harvard-MIT Division of Health Sciences and Technology, and Industrial Technology Research Institute (Taiwan). The DISPERSE2 trial was supported by AstraZeneca.

PII: S0002-9149(08)01676-7

doi:10.1016/j.amjcard.2008.09.099

American Journal of Cardiology
Volume 103, Issue 3 , Pages 307-311, 1 February 2009